Texas Oncology Austin-Midtown — Austin, Texas

Public research footprint of Texas Oncology Austin-Midtown, compiled from the ClinicalTrials.gov public registry.

Registered studies

Active

Recruiting now

Completed

Stopped or withdrawn

Most-studied conditions

Advanced Solid Tumor · Anatomic Stage IV Breast Cancer American Joint Committee on Cancer… · Relapsed or Refractory Diffuse Large B-Cell Lymphoma · Metastatic Castration Resistant Prostate Cancer (mCRPC)

Recently updated registry entries

NCT06820463 — A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab… (Recruiting)
NCT06191744 — Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral… (Active Not Recruiting)
NCT06635824 — Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of… (Active Not Recruiting)

7 more recent registry entries at this facility

Enter your work email to view the full list.

I’d also like to receive occasional marketing emails from Eichor for research sites (optional — unsubscribe anytime).

Work at Texas Oncology Austin-Midtown?

Verify and correct how your facility appears in public registry records — free.

Verify this profile →

Compiled from public registry records (ClinicalTrials.gov) as of August 06, 2026. Counts reflect how this facility appears in registry listings; name variants may exist and are not combined. This page describes public records only and makes no assessment of any facility.